|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 11,266,607
United States Patent 11,266,607, titled "Combination therapy comprising exosome-derived therapeutic agents and immunomodulatory antibodies," claims a novel therapeutic approach involving the co-administration of exosome-derived agents and immunomodulatory antibodies for treating various diseases, including cancer and autoimmune disorders. The patent, issued on February 15, 2022, to Regeneron Pharmaceuticals, Inc., aims to enhance treatment efficacy by leveraging the synergistic effects of these two therapeutic modalities.
What is the Core Invention Claimed in US Patent 11,266,607?
The central innovation patented is a therapeutic combination comprising:
- Exosome-derived therapeutic agents: These agents are derived from exosomes, which are small extracellular vesicles released by cells. The patent specifies that these exosomes can be engineered or naturally derived and carry therapeutic payloads, such as nucleic acids (e.g., mRNA, siRNA, miRNA) or proteins, designed to modulate cellular function.
- Immunomodulatory antibodies: These antibodies are designed to interact with specific targets within the immune system to either activate or suppress immune responses. Examples include antibodies targeting immune checkpoints (e.g., PD-1, PD-L1, CTLA-4) or other immune signaling molecules.
The patent claims encompass methods of treating diseases by administering these components simultaneously or sequentially. The intended mechanism of action is to enhance the delivery and efficacy of therapeutic payloads from exosomes, while simultaneously modulating the immune microenvironment to promote anti-tumor immunity or dampen autoimmune inflammation.
The patent outlines specific disease indications, including:
- Cancer: Melanoma, lung cancer, breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, glioblastoma, and leukemia.
- Autoimmune Diseases: Rheumatoid arthritis, lupus erythematosus, multiple sclerosis, type 1 diabetes, and inflammatory bowel disease.
Key claims within the patent specify combinations of particular exosome compositions with specific types of immunomodulatory antibodies. For instance, claim 1 broadly covers "A combination therapy comprising: (a) at least one exosome-derived therapeutic agent comprising a therapeutic payload encapsulated within or associated with an exosome; and (b) at least one immunomodulatory antibody." Subsequent claims narrow down the scope, specifying the nature of the therapeutic payload (e.g., mRNA encoding a tumor antigen or an immune-stimulatory protein), the source of the exosomes (e.g., engineered cells), and the target of the antibody (e.g., PD-1 receptor or PD-L1 ligand).
What is the Technical Background and Rationale for this Combination Therapy?
The rationale behind combining exosome-derived therapeutic agents with immunomodulatory antibodies stems from the limitations of each modality when used alone.
Exosome-Derived Therapeutic Agents:
Exosomes are naturally occurring nanoparticles that possess several advantageous properties for drug delivery:
- Biocompatibility: Being derived from biological membranes, exosomes exhibit low immunogenicity and good biocompatibility, potentially reducing adverse reactions compared to synthetic nanoparticles [1].
- Targeted Delivery: Exosomes can be engineered to target specific cell types by displaying surface ligands or by selecting exosomes from cells with inherent targeting capabilities. This can improve drug accumulation at the disease site and reduce off-target effects.
- Payload Protection and Delivery: The lipid bilayer of exosomes can protect encapsulated therapeutic molecules, such as nucleic acids, from degradation in the biological environment. They can also facilitate intracellular delivery.
- Immune Modulation: Some studies suggest exosomes themselves can possess immunomodulatory properties, either by carrying specific surface proteins or by influencing antigen presentation.
However, challenges remain in the large-scale production of therapeutic-grade exosomes and achieving consistent therapeutic payloads and targeting efficiency.
Immunomodulatory Antibodies:
Antibodies, particularly those targeting immune checkpoints, have revolutionized cancer immunotherapy. These antibodies work by blocking inhibitory pathways that cancer cells exploit to evade the immune system, thereby unleashing T cell-mediated anti-tumor responses.
- PD-1/PD-L1 Inhibitors: Block the interaction between PD-1 on T cells and PD-L1 on tumor cells or other immune cells, restoring T cell activity.
- CTLA-4 Inhibitors: Block CTLA-4, another inhibitory receptor on T cells, promoting T cell activation and proliferation.
While highly effective for certain patient populations, checkpoint inhibitors often exhibit limited response rates, and some patients develop resistance or experience immune-related adverse events.
Synergistic Rationale:
The combination aims to address these limitations through synergy:
- Enhanced Antigen Presentation: Exosomes carrying tumor-associated antigens or immunostimulatory proteins could prime the immune system, making it more responsive to the subsequent or concurrent administration of immunomodulatory antibodies. The antibodies then act to lift the brakes on this primed immune response.
- Improved Exosome Efficacy: The altered immune microenvironment induced by antibodies might enhance the uptake and efficacy of exosome-derived payloads. For example, by reducing immunosuppressive cells in the tumor microenvironment, antibodies could facilitate immune cell infiltration and subsequent effector functions triggered by the exosome therapy.
- Broadened Therapeutic Window: The combination might allow for lower doses of each agent, potentially reducing toxicity while achieving superior efficacy compared to monotherapy.
- Overcoming Resistance: The dual mechanism of action could help overcome resistance to single-agent therapies.
What is the Patent Landscape for Exosome-Based Therapies and Immunomodulatory Antibodies?
The patent landscape surrounding exosome-based therapies and immunomodulatory antibodies is dynamic and highly competitive, with significant activity from major pharmaceutical and biotechnology companies.
Immunomodulatory Antibodies:
The field of immunomodulatory antibodies, particularly checkpoint inhibitors, is mature, with numerous patents covering specific antibodies, their targets, therapeutic uses, and manufacturing processes. Key players include:
- Merck & Co.: Known for Keytruda (pembrolizumab), a PD-1 inhibitor.
- Bristol Myers Squibb: Known for Opdivo (nivolumab) and Yervoy (ipilimumab), PD-1 and CTLA-4 inhibitors, respectively.
- Roche: Known for Tecentriq (atezolizumab), a PD-L1 inhibitor.
- AstraZeneca: Known for Imfinzi (durvalumab), a PD-L1 inhibitor.
Patents in this area often focus on specific antibody sequences, methods of use for particular cancer types or combinations, and biomarkers for patient selection. The expiry of early patents for some of these blockbuster drugs has led to increased generic and biosimilar competition, shifting patent focus towards novel antibody formats, combination therapies, and next-generation checkpoint inhibitors.
Exosome-Based Therapies:
The patent landscape for exosome-based therapies is rapidly evolving and less consolidated than that of antibodies. Patents generally fall into categories:
- Exosome Isolation and Production: Methods for efficient isolation, purification, and large-scale production of exosomes from various cell sources (e.g., stem cells, engineered cell lines).
- Exosome Engineering: Methods for modifying exosomes to carry specific therapeutic payloads (e.g., genetic material, proteins) or to enhance their targeting capabilities (e.g., surface modification with ligands).
- Therapeutic Applications: Patents covering the use of exosomes for delivering specific therapeutic agents to treat particular diseases, including cancer, neurological disorders, and inflammatory conditions.
- Combination Therapies: Patents claiming combinations of exosome-based therapies with other treatment modalities, such as chemotherapy, radiation, or other immunotherapies, similar to US Patent 11,266,607.
Key players in the exosome space include academic institutions and emerging biotechnology companies, though major pharmaceutical companies are increasingly investing in this area through partnerships and internal development. Examples of companies filing patents in this domain include:
- Codiak BioSciences: Focused on engineered exosomes for drug delivery.
- Evox Therapeutics: Developing exosome-based therapeutics.
- ExoCyte Therapeutics: Researching exosome applications.
The patentability of exosome-based therapies often hinges on demonstrating novelty and non-obviousness in the methods of isolation, engineering, or specific therapeutic applications. Claims need to clearly define the composition of the exosome preparation, the nature of the therapeutic payload, and the intended use.
Intersection of Exosomes and Immunomodulatory Antibodies:
US Patent 11,266,607 represents a specific intersection within this broader landscape, claiming a combination therapy. The novelty here lies in the claimed synergy and the specific combination of exosome-derived agents with immunomodulatory antibodies.
- Prior Art Considerations: The patentability of this invention would have been assessed against existing patents and scientific literature related to exosome delivery, immunotherapy, and combination treatments. Examiners would have scrutinized whether the claimed combination was obvious in light of known technologies.
- Competitive Landscape: Other entities are likely pursuing similar combination strategies. Companies developing exosome platforms and those with established immunomodulatory antibody portfolios would be natural competitors in exploring such synergistic approaches. Patent filings in this specific niche would focus on:
- Unique exosome engineering strategies for enhanced immune priming.
- Novel antibody targets or combinations with exosomes.
- Specific disease indications where the combination shows superior efficacy.
- Methods for optimizing the dosing and scheduling of the combined agents.
The issuance of this patent to Regeneron Pharmaceuticals, Inc. suggests that their claims were deemed novel and non-obvious by the USPTO, positioning them with exclusive rights to this specific combination therapy approach within the United States for the patent's term.
What are the Specific Claims and Scope of Protection Offered by US Patent 11,266,607?
US Patent 11,266,607 contains a series of independent and dependent claims that define the scope of protection. The breadth of protection can be understood by examining the key claims.
Independent Claims:
-
Claim 1: This foundational claim broadly defines a "combination therapy" comprising:
- (a) at least one exosome-derived therapeutic agent, where the agent includes a therapeutic payload encapsulated within or associated with an exosome.
- (b) at least one immunomodulatory antibody.
This claim establishes the core inventive concept—the co-administration of these two distinct therapeutic entities. The terms "therapeutic payload" and "exosome-derived therapeutic agent" are broad, allowing for various types of encapsulated materials and exosome sources. "Immunomodulatory antibody" is also broadly defined, encompassing antibodies that can activate or inhibit immune responses.
-
Claim 13: This claim focuses on a method of treating a disease using the combination therapy described in Claim 1. It covers "A method of treating a disease in a subject, the method comprising administering to the subject a therapeutically effective amount of: (a) at least one exosome-derived therapeutic agent comprising a therapeutic payload encapsulated within or associated with an exosome; and (b) at least one immunomodulatory antibody."
This claim directly relates to the practical application of the invention for therapeutic purposes. The definition of "disease" and "subject" is also broad, underscoring the wide applicability intended.
Dependent Claims and Limitations:
Dependent claims progressively narrow the scope of the independent claims by adding specific limitations. These limitations are crucial for understanding the practical boundaries of the patent's protection.
-
Nature of the Therapeutic Payload: Several dependent claims specify the type of therapeutic payload within the exosomes. Examples include:
- Nucleic acids (e.g., mRNA, siRNA, miRNA) [Dependent on Claim 1].
- mRNA encoding a tumor antigen, an immune-stimulatory protein, or a protein involved in modulating an immune response [Dependent on Claim 1].
- Proteins, including cytokines or enzymes [Dependent on Claim 1].
-
Source of Exosomes: Claims may also specify the origin or type of exosomes:
- Exosomes derived from mammalian cells [Dependent on Claim 1].
- Exosomes derived from engineered cells [Dependent on Claim 1].
- Exosomes having specific surface markers or modifications [Dependent on Claim 1].
-
Type of Immunomodulatory Antibody: Limitations are placed on the immunomodulatory antibodies:
- Antibodies targeting immune checkpoint proteins such as PD-1, PD-L1, or CTLA-4 [Dependent on Claim 1].
- Antibodies that inhibit the binding of PD-1 to PD-L1, or CTLA-4 to its ligand [Dependent on Claim 1].
- Specific antibody sequences or humanized antibodies [Dependent on Claim 1].
-
Therapeutic Indications: Specific diseases for which the combination therapy is claimed:
- Cancer, including melanoma, lung cancer, breast cancer, colorectal cancer, prostate cancer, pancreatic cancer, glioblastoma, and leukemia [Dependent on Claim 13].
- Autoimmune diseases, including rheumatoid arthritis, lupus erythematosus, multiple sclerosis, type 1 diabetes, and inflammatory bowel disease [Dependent on Claim 13].
-
Administration Regimen: Claims may cover specific ways the combination is administered:
- Administered simultaneously [Dependent on Claim 13].
- Administered sequentially [Dependent on Claim 13].
- Exosomes administered before the antibody, or vice versa [Dependent on Claim 13].
Key Aspects of Protection:
- Composition of Matter: Claims 1 and related dependent claims protect the therapeutic composition itself – the physical combination of exosome-derived agents and immunomodulatory antibodies. This means anyone making, using, or selling this specific combination without a license would infringe.
- Method of Use: Claim 13 and its dependents protect the specific methods of treating diseases using this combination. This covers healthcare providers administering the therapy and potentially manufacturers selling the products for those specific uses.
- Breadth vs. Specificity: The broad independent claims provide a wide potential scope. However, the validity and enforceability of these broad claims rely on the novelty and non-obviousness of the core invention over prior art. The dependent claims provide more specific, arguably stronger, protection for particular embodiments of the invention. For instance, a claim specifying a particular mRNA payload within engineered exosomes combined with an anti-PD-1 antibody for treating melanoma would have a narrower but potentially more defensible scope than the broadest claim.
The patent's claims define a significant potential market for combination therapies, particularly in oncology and immunology. Competitors seeking to develop similar combination treatments must carefully navigate this patent to avoid infringement.
What are the Potential Commercial Implications and Competitive Threats?
The issuance of US Patent 11,266,607 to Regeneron Pharmaceuticals, Inc. has several significant commercial implications and signals potential competitive threats for other entities operating in the oncology and immunology therapeutic spaces.
Commercial Implications for Regeneron:
- Market Exclusivity: The patent grants Regeneron exclusive rights to commercialize the claimed combination therapy in the United States for the patent's term (typically 20 years from the filing date, subject to patent term adjustments). This exclusivity provides a significant competitive advantage and the opportunity to capture market share.
- Licensing Opportunities: Regeneron can leverage this patent to license the technology to other companies, potentially generating royalty revenue. This is particularly relevant if Regeneron focuses on developing one arm of the combination (e.g., an exosome platform) and licenses out the other (e.g., their antibody portfolio), or vice versa.
- Platform Development: The patent supports Regeneron's strategy in developing exosome-based drug delivery platforms. It validates their investment in this emerging technology and positions them as a leader in combining engineered exosomes with advanced immunotherapies.
- Pipeline Enhancement: This patent adds a potentially high-value asset to Regeneron's pipeline, particularly in areas with unmet medical needs like refractory cancers and autoimmune diseases. The combination therapy could become a significant revenue driver if successful in clinical trials.
Competitive Threats and Considerations:
- Freedom-to-Operate (FTO) Analysis: Competitors developing or considering similar combination therapies must conduct thorough FTO analyses. This involves assessing whether their planned products or methods infringe on the claims of US Patent 11,266,607. Potential infringement could arise from developing therapies that utilize:
- The specific composition of exosome-derived agents and immunomodulatory antibodies as claimed.
- Methods of treating the specified diseases using this combination.
- Patent Challenges (Inter Partes Review): Competitors may consider challenging the validity of the patent through mechanisms like Inter Partes Review (IPR) at the USPTO. Such challenges would aim to invalidate the patent's claims based on prior art that may have been overlooked by the patent examiner. Successful invalidation would remove the exclusivity barrier.
- Alternative Exosome Engineering or Antibody Targets: Competitors might circumvent the patent by:
- Developing exosome-derived agents with different therapeutic payloads or engineering methods that do not fall under the patent's claims.
- Using immunomodulatory antibodies targeting different pathways or with distinct properties that are not covered by the patent's limitations.
- Focusing on therapeutic indications not explicitly claimed in the patent.
- Early-Stage Research vs. Commercialization: While the patent provides protection for commercialization, early-stage academic or preclinical research that does not involve commercial activity may not be directly impacted, though reporting findings might require careful consideration of the patent's scope.
- Global Patent Strategy: US Patent 11,266,607 is specific to the United States. Competitors operating globally will need to assess Regeneron's patent protection in other key markets (e.g., Europe, Japan, China), as similar patent applications may have been filed or granted, or they may be subject to different prior art landscapes.
- Biosimilar/Generic Competition: For the immunomodulatory antibody component, if it is a known antibody whose patent has expired or is expiring, competitors might aim to develop biosimilars. However, the combination aspect with proprietary exosome technology adds a layer of complexity to biosimilar development and market entry.
The patent underscores the strategic importance of combination therapies in modern drug development. Companies must balance innovation with a comprehensive understanding of the existing patent landscape to mitigate risks and identify opportunities.
Key Takeaways
- US Patent 11,266,607 protects a combination therapy involving exosome-derived therapeutic agents and immunomodulatory antibodies for treating cancer and autoimmune diseases.
- The invention leverages the synergistic potential of exosome delivery systems and immune checkpoint blockade or modulation.
- The patent grants Regeneron Pharmaceuticals, Inc. exclusive rights in the U.S. for the claimed compositions and methods of use, impacting competitors' freedom to operate.
- Competitors may need to navigate around the patent through alternative technologies, different therapeutic targets, or by challenging its validity.
FAQs
-
What specific diseases are covered by US Patent 11,266,607?
The patent covers a range of cancers, including melanoma, lung, breast, colorectal, prostate, pancreatic, glioblastoma, and leukemia, as well as autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, multiple sclerosis, type 1 diabetes, and inflammatory bowel disease.
-
Does this patent cover any exosome therapy or any immunomodulatory antibody individually?
No, the patent specifically claims the combination of exosome-derived therapeutic agents and immunomodulatory antibodies. It does not grant exclusivity over either component when used alone.
-
What types of therapeutic payloads can be encapsulated in the exosomes according to this patent?
The patent broadly covers payloads such as nucleic acids (mRNA, siRNA, miRNA) and proteins, including those encoding tumor antigens, immune-stimulatory proteins, or other molecules that modulate immune responses.
-
What is the primary benefit of combining these two therapeutic modalities as claimed in the patent?
The claimed benefit is synergy, aiming to enhance treatment efficacy by improving exosome delivery and payload effectiveness, while simultaneously modulating the immune microenvironment to promote anti-tumor immunity or reduce autoimmune inflammation.
-
How can a company avoid infringing on US Patent 11,266,607 if they are developing a similar combination therapy?
Companies can avoid infringement by conducting thorough freedom-to-operate analyses to ensure their specific composition, method of use, or therapeutic targets do not fall within the patent's claims. Alternative strategies include developing different therapeutic payloads, using distinct types of exosomes, targeting different immune pathways with antibodies, or focusing on indications not covered by the patent.
Citations
[1] Johnsen, K. G., Van de Ven, A. L., & Graf, R. T. (2014). Cargo of the cell's discard pile: the true biological function of exosomes. Annual Review of Biochemistry, 83, 107-130.
More… ↓
⤷ Start Trial
|
